Navigation Links
New myeloma drug shows promise in early testing
Date:6/7/2010

ANN ARBOR, Mich. A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center. Jakubowiak presented results of the study at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Drug shows positive responses, low side-effects in multiple myeloma
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. Experimental targeted therapy shows early promise against medulloblastomas
5. Targeted Therapy Shows Promise Against Deadly Brain Cancer
6. Selenium shows no benefit in prevention of lung cancer
7. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
8. Spending time in nature makes people feel more alive, study shows
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Prostate Cancer Vaccine Shows Few Side Effects
11. Brief Exercise Reduces Impact of Stress on Cell Aging, UCSF Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Palo Alto, CA (PRWEB) , ... ... ... Translations, a provider of translation and localization services for life science companies, ... testing and inspection organization, TÜV SÜD America. ISO 17100 is the globally ...
(Date:1/23/2017)... ... 2017 , ... DMG Productions is proud to announce the ... to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will educate ... the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap is ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, President of the ... healthcare industry expert at the 2017 Sector Summit hosted by Ivy Tech Community ... host Gerry Dick, will feature an employer and an association representative from five ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... -- Just two weeks remain until legal experts and senior industry leaders ... Central London to discuss the flow of pharmaceutical products post ... Parallel Trade 2017 . In the run up to the ... available to read in the event download centre . ... Some of those confirmed include: ...
Breaking Medicine Technology: